Helicos BioSciences Announces First Order for the Helicos™ Genetic Analysis Platform

Helicos BioSciences Corporation

Helicos BioSciences Announces First Order for the Helicos™ Genetic Analysis Platform

February 8, 2008

Life Science Company Continues to Define a New Category in Sequencing

CAMBRIDGE, Mass., Feb 08, 2008 (BUSINESS WIRE) -- Helicos BioSciences (NASDAQ: HLCS), a life science company focused on innovative genetic analysis technologies, today announced its first order for the Helicos™ Genetic Analysis System. The system consists of the HeliScope™ Single Molecule Sequencer, the HeliScope™ Analysis Engine, and the HeliScope™ Sample Loader, all designed for production-level genetic analysis. Central to the platform is the company's proprietary sequencing-by-synthesis approach called True Single Molecule Sequencing (tSMS)™.

"This first order is an important milestone for both the company and for the scientific community," said Steve Lombardi, Helicos BioSciences' president and COO. "In just three years, the talented and dedicated Helicos team has delivered on the promise of single molecule sequencing, which has been a goal of the scientific community since Watson and Crick's discovery of DNA."

Helicos' proprietary tSMS™ technology directly sequences single molecules of DNA or RNA, a process that significantly increases the speed of sequencing, while also decreasing the cost. The company's sequencing-by-synthesis approach differs from current methods of sequencing DNA as it analyzes individual molecules of DNA directly as opposed to analyzing a large number of copies of the molecule produced through complex sample preparation techniques. In turn, Helicos' technology provides the workflow that is based on a simple, cost effective sample preparation process.

The HeliScope Single Molecule Sequencer is able to image billions of bases in a single run. In addition, the HeliScope Analysis Engine provides real-time image processing which results in continuous processing of samples meeting the requirements of large, complex experiments envisioned by the research community.

"We are extremely pleased that our first customer, skilled in a wide variety of genetic analysis applications, shares our vision of enabling researchers with the tools to accelerate our knowledge of the genome and ultimately usher in the era of personalized medicine," said Chip Leveille, vice president of Sales and Marketing at Helicos BioSciences. "Helicos' ability to make true direct DNA measurements enables new experimentation that is fundamental to the sound science of the genome for an understanding of disease and treatment."

About Helicos BioSciences

Helicos BioSciences is a life science company focused on innovative genetic analysis technologies for the research, drug discovery, and diagnostic markets. Helicos' proprietary True Single Molecule Sequencing, tSMSTM, technology allows direct measurement of billions of strands of DNA enabling scientists to perform experiments and ask questions never before possible. The company's corporate headquarters are located at One Kendall Square, Building 700, Cambridge, MA 02139, and its telephone number is (617) 264-1800.

Certain statements made in this press release that are not based on historical information are forward-looking statements which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. This press release contains express or implied forward-looking statements relating to, among other things, Helicos' expectations concerning the fulfillment of the first order discussed in this press release and management's plans, objectives and strategies. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond Helicos' control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, the risks and uncertainties include, among other things, our ability to successfully complete the manufacturing process and commercialize the HeliScope system; competition; changing technology and customer acceptance requirements; our ability to operate in an emerging market; market acceptance of our technology; our ability to retain our personnel and hire additional skilled personnel; our ability to manage our rapid growth and our ability to obtain capital when desired on favorable terms. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Helicos undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. For additional disclosure regarding these and other risks faced by Helicos, see the disclosure contained in Helicos' public filings with the Securities and Exchange Commission.


Investor Relations:
Helicos BioSciences Corporation
Louise Mawhinney, 617-264-1800
Sr. Vice President and Chief Financial Officer


Media Contact:
Racepoint Group
Sally Bain, 781-487-4647